PCV33 MODELING THE ECONOMIC IMPACT OF NEW IMPLANTABLE DEFIBRILLATORS WITH A LONGER LIFETIME
To analyse the cost-effectiveness of anticoagulation with bivalirudin compared to heparin and GlycoProtein Inhibitors IIb/IIIa (GPIs) in patients undergoing Percutaneous Coronary Intervention (PCI) in Sweden. METHODS: As treatment practice varies between hospitals, e.g. the fraction of patients receiving GPI varies, the model analyses a patient cohort where heparin is combined with GPIs to a variable percentage (% GPIs) and the remaining patients receive heparin monotherapy. The Swedish Council on Technology Assessment in Health Care has estimated that GPIs are being used in a range of 40-50% of all PCIs. Abciximab is the only GPI with indication for PCI in Sweden, and it was therefore used as the comparator. Pooled data from applicable studies (REPLACE-2, EPISTENT, ESPRIT), provided probabilities for the events; death, myocardial infarction (MI), urgent revascularisation (UR) and major and minor bleedings according to the TIMI definitions. Treatment costs (year 2004) were collected for each complication from four Swedish hospitals, and official drug prices from the Swedish pharmacopeia. The model was evaluated using stochastic evaluation, in a Swedish Health Care perspective, in a 30-day time frame. The modelled patient population was on average 63 years of age, 75% male. RESULTS: Compared to a 40-50% usage of GPIs, treatment with bivalirudin reduced (p < 0.05) all complications (e.g. by 9.3 MIs, 1.9 URs, 14.4 bleedings and 1.5 deaths in 1000 treated patients, of which 40% received a GPI), and at the same time significantly reduced total costs for drugs and health care (87 SEK/patient, 95% CI 21 to 157 at 40% GPIs, or 935 SEK/patient, 95% CI 867 to 997 at 50% GPIs). CONCLUSIONS: Treatment with bivalirudin as compared to heparin and GPIs, significantly reduced all studied complications, and resulted in significant savings in total costs of drugs and health care in Sweden. Assess cost-effectiveness of switching patients to ezetimibe 10 mg (EZ10) co-administration with simvastatin 20 mg (S20) versus an atorvastatin titration strategy (patients are titrated to goal or maximum atorvastatin dose of 80 mg) in CHD and CHD equivalent patients not at goal with atorvastatin 10 mg (A10) monotherapy. Method: Decision-analytic model
PCV35 ECONOMIC ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH SIMVASTATIN IN SPAIN FOR A COHORT OF PATIENTS NOT AT GOAL ON ATORVASTATIN MONOTHERAPY
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